1. Introduction {#sec1-ijms-17-01221}
===============

Pertaining to the frequency of diagnosis worldwide, breast cancer is regarded as the second most frequently diagnosed cancer and the most frequently diagnosed tumor among women. Also, it is regarded as the fifth leading cause of cancer mortality \[[@B1-ijms-17-01221]\]. In 2012, an estimated 1.67 million newly diagnosed breast cancer cases and 522,000 breast cancer deaths occurred worldwide \[[@B1-ijms-17-01221]\]. The etiology of breast cancer is still unknown, although different risk factors have been established---to name just a few, first-degree relative's breast cancer family history, mammographic density, benign breast disease, younger age at menarche, low parity, older age at first birth, older age at menopause, high postmenopausal body mass index, low premenopausal body mass index, and endogenous hormone levels have been established as risk factors for breast cancer \[[@B2-ijms-17-01221],[@B3-ijms-17-01221]\].

Breast cancer is regarded as a diverse group of diseases with multiple intrinsic tumor subtypes that have various treatment modalities and long-term survival probabilities. The immunohistochemical expression of the estrogen receptor (ER), progesterone receptor (PR), and human epidermal growth factor receptor-2 (HER-2) forms the platform of characterization of clinically defined breast cancer subtypes \[[@B4-ijms-17-01221]\]. In approximately 15%--20% of globally diagnosed breast cancers, the tumors do not express ER, PR, or HER-2. Such malignancies are designated as triple-negative breast cancer (TNBC) \[[@B5-ijms-17-01221]\].

In the current medical era, TNBC, among all the breast cancer subgroups, has stood out as the greatest clinical challenge as these tumors have no clinically validated molecularly targeted therapy, are prevalent in younger women, associated with the worst prognosis, and often relapse rapidly. Also, TNBC are highly proliferative, poorly differentiated, often grade III carcinomas, genetically unstable, and preferentially metastasize to the brain and lungs \[[@B6-ijms-17-01221],[@B7-ijms-17-01221],[@B8-ijms-17-01221],[@B9-ijms-17-01221],[@B10-ijms-17-01221]\]. Therefore, there is a critical need to develop potent and effective novel therapies to improve the outcomes of TNBC treatment.

Because of their similarity to some naturally occurring nucleotides and their existence in several naturally occurring compounds, benzimidazole derivatives possess a wide range of biological activities and therapeutic effects \[[@B11-ijms-17-01221],[@B12-ijms-17-01221],[@B13-ijms-17-01221]\]. In the field of medicinal chemistry, benzimidazole represents a highly privileged scaffold and has been copiously explored as an anti-proliferative agent targeting different breast cancer cells \[[@B14-ijms-17-01221],[@B15-ijms-17-01221],[@B16-ijms-17-01221],[@B17-ijms-17-01221],[@B18-ijms-17-01221],[@B19-ijms-17-01221],[@B20-ijms-17-01221],[@B21-ijms-17-01221]\]. Surveying the literature revealed that different benzimidazole-based scaffolds were developed with significant activity toward the TNBC MDA-MB-468 cells in the anticancer drug screening program of the U.S. National Cancer Institute (NCI), according to their applied protocol against full NCI 60 human cell lines panel ([Figure 1](#ijms-17-01221-f001){ref-type="fig"}).

Many researchers have reported the utility of 2-aryl benzimidazole derivatives as anti-proliferative agents against TNBC. Attaching a heterocyclic moiety, 5-*tert*-butyl-1*H*-pyrazol-3-yl, in position 1 and an aryl moiety, 4-chlorophenyl, in position 2 of benzimidazole core resulted in compound **I** (NSC: 751047) with good anti-proliferative activity against MDA-MB-468 (IC~50~ = 2.4 µM) \[[@B22-ijms-17-01221]\] ([Figure 1](#ijms-17-01221-f001){ref-type="fig"}), while substitution of position 2 of 5-flouro and 5-methoxybenzimidazole with 1,2,4-oxadiazole moiety through a phenyl ring afforded compounds **II** and **III**, respectively, (NSC: 761109 and 761814) with IC~50~ values of 3.01 and 6.54 µM, respectively, against MDA-MB-468 \[[@B23-ijms-17-01221]\] ([Figure 1](#ijms-17-01221-f001){ref-type="fig"}). Moreover, introduction of different aryl groups through a pyrazole linker at position 2 of the benzimidazole core, as in compounds **IV** and **V** (NSC: 768400 and 768399), achieved significant efficacy against MDA-MB-468 (IC~50~ values of 0.93 and 3.5 µM, respectively) \[[@B24-ijms-17-01221]\] ([Figure 1](#ijms-17-01221-f001){ref-type="fig"}). Interestingly, linking different aryl moeities, through variable heterocyclic groups, via a three-atom linker, namely a propan-1-one group to position 2 of the benzimidazole core led to compounds **VI**--**VIII** (NSC: 761980, NSC: 759205 and NSC: 7604520) with low or sub-micromolar anti-proliferative activity against MDA-MB-468 (IC~50~ = 1.93, 0.79 and 0.69 µM, respectively) \[[@B25-ijms-17-01221],[@B26-ijms-17-01221],[@B27-ijms-17-01221]\] ([Figure 1](#ijms-17-01221-f001){ref-type="fig"}).

In addition, we recently introduced an efficacious benzimidazole-based scaffold as for development of potent antitumor agents that prove to have anti-proliferative activity not only toward the cancer stem cells but also toward the bulk of tumor cells of the colon HT-29 cell line \[[@B28-ijms-17-01221]\]. The design of such a scaffold relies on linking different aryl or heteroaryl groups to position 2 of the benzimidazole core through a thio ethan-2-one linker. From the findings reported above, we came to the conclusion that linking the 2-position of benzimidazole scaffold to a terminal aryl or heteroaryl group directly or via variable spacers---an aryl, a heteroaryl, or a propan-1-one group---affords promising molecules that have significant anti-proliferative activity against TNBC.

Regarding these points and as a continuation of our research program on the design and synthesis of effective antitumor candidates \[[@B29-ijms-17-01221],[@B30-ijms-17-01221],[@B31-ijms-17-01221],[@B32-ijms-17-01221],[@B33-ijms-17-01221],[@B34-ijms-17-01221],[@B35-ijms-17-01221]\], it was thought worthwhile to extend our investigations around our study \[[@B28-ijms-17-01221]\] to probe for benzimidazole derivatives having anti-proliferative activity towards TNBC. Our structure-based design was three-fold: (i) preserving benzimidazole structure with subsitution at 2-position; (ii) maintaining a terminal lipophilic group; and (iii) establishing a three-atom thio ethane-1-one linker to afford more flexibility for the designed molecules ([Figure 2](#ijms-17-01221-f002){ref-type="fig"}). Thus, the present work reports the synthesis of benzimidazoles **5a**--**w** and their in vitro anti-proliferative activity against the TNBC MDA-MB-468 cell line. Moreover, the most active member in this study, **5k**, was selected to be further investigated regarding its effects on cell cycle progression and potential apoptotic effect in the MDA-MB-468 cells, to acquire perception of the mechanism of the anti-proliferative activity of the prepared compounds. Eventually, a theoretical kinetic study was constituted.

2. Results {#sec2-ijms-17-01221}
==========

2.1. Synthetic Approach to Prepare the Target Derivatives {#sec2dot1-ijms-17-01221}
---------------------------------------------------------

The target compounds were prepared following our recently published procedure \[[@B28-ijms-17-01221]\] via the reaction of compound **2** with different aromatic ketones **3a**--**w** in glacial acetic acid in the presence of two equivalents conc. H~2~SO~4~ to afford a quantitative yield from the sulfate salts **4a**--**w**. The prepared sulfate salts **4a**--**w** were subsequently neutralized to afford the target 2-((benzimidazol-2-yl)thio)-1-arylethan-1-ones **5a**--**w** in an excellent yield of 82%--96% ([Scheme 1](#ijms-17-01221-sch001){ref-type="scheme"}).

Infrared (IR) spectra for compounds **5a**--**w** displayed absorption bands attributable for the NH group in the range 3324--3460 cm^−1^, also a (C=O) band in the range of 1654--1690 cm^−1^. Also, their ^1^H-nuclear magnetic resonance (NMR) spectra displayed one singlet D~2~O-exchangeable signal due to the NH proton in the range of δ 12.52--12.80 ppm, whereas (--CH~2~--) protons appeared as singlet signals within δ 5.00 ppm. Furthermore, the ^13^C-NMR spectra of compounds **5a**--**w** showed signals resonating in the region δ 182.16--193.90 ppm due to the carbon of carbonyl group, whereas the carbons of the (--CH~2~--) group appeared in the region of δ 38.46--43.97 ppm.

2.2. Single Crystal Analysis of Compounds **4u** and **5v** {#sec2dot2-ijms-17-01221}
-----------------------------------------------------------

Crystals of compounds **4u** and **5v** were selected to analyze their single-crystal X-ray crystallographic after slow evaporation from solutions of ethanol. The instrument used is Bruker SMART APEX II D8 Venture diffractometer (Bruker, Karlsruhe, Germany) with graphite-monochromated Mo *K*α radiation (λ = 0.71073 Å) at 100 and 150 K, respectively. A direct method was applied to solve the structures that were subsequently refined with SHELXTL \[[@B36-ijms-17-01221]\]. The positions of all the non-H-atoms were provided by E-maps. Using anisotropic temperature factors, the full-matrix least-squares refinement was carried out on *F*^2^'s for all non-H-atoms. Crystallographic data was deposited in the Cambridge Crystallographic Data Center and assigned the following deposition numbers: CCDC 1058838 and 1455648 for compounds **4u** and **5v**, respectively.

In [Figure 2](#ijms-17-01221-f002){ref-type="fig"} and [Figure 3](#ijms-17-01221-f003){ref-type="fig"}, the crystallographic structures of compounds **4u** and **5v** are represented, respectively. The exact structure is unambiguously defined by the single crystal X-ray study on both derivatives. The crystal structure of **4u** confirmed two crystallographically independent cation molecules with one sulfate anion, in the presence of one molecule of ethanol in its asymmetric unit, as shown in [Figure 3](#ijms-17-01221-f003){ref-type="fig"}. The asymmetric unit of **5v** contains one molecule only, as depicted in [Figure 4](#ijms-17-01221-f004){ref-type="fig"}. [Table 1](#ijms-17-01221-t001){ref-type="table"} listed the crystallographic data and the refinement for the crystals. [Table 2](#ijms-17-01221-t002){ref-type="table"} and [Table 3](#ijms-17-01221-t003){ref-type="table"} summarized some selected geometric parameters for **4u** and **5v**, respectively. Also, [Figure S1](#app1-ijms-17-01221){ref-type="app"} (in [Supplementary Materials](#app1-ijms-17-01221){ref-type="app"}) displayed the molecular packing of compound **5v**, while [Table S1](#app1-ijms-17-01221){ref-type="app"} showed the hydrogen-bond geometry (Å, °) for compound **5v**.

2.3. Biological Evaluation of the Target Derivatives as Anti-Cancer Agents {#sec2dot3-ijms-17-01221}
--------------------------------------------------------------------------

### 2.3.1. In Vitro Anti-Proliferative Activity against MDA-MB-468 {#sec2dot3dot1-ijms-17-01221}

The WST-1 assay, as described by Ngamwongsatit et al. \[[@B37-ijms-17-01221]\], was adopted to evaluate the anti-proliferative activity of the synthesized 2-((benzimidazol-2-yl)thio)-1-arylethan-1-ones **5a**--**w** against human breast cancer cell line MDA-MB-468. 5-FU (florouracil) was selected as a positive control due to its broad spectrum of anticancer activity. The anti-proliferative activity was expressed as growth inhibitory concentration (IC~50~) values, which represent the compound concentrations required to produce a 50% inhibition of cell growth after 48 hours of incubation compared to untreated controls ([Table 4](#ijms-17-01221-t004){ref-type="table"}).

The obtained results of the tested benzimidazole derivatives **5a**--**w** indicated that most of the prepared compounds showed good to moderate anti-proliferative activity against the tested MDA-MB-468 cancer cell line. Compound **5k** merged as the most potent member against MDA-MB-468 (IC~50~ = 19.90 ± 1.37 µM) as it was 2.1 times more potent and efficacious than 5-fluorouracil (IC~50~ = 41.26 ± 3.77 µM). Moreover, analogs **5a**, **5f**, and **5j**--**t** showed superior anti-proliferative activity (IC~50~ values ranging from 21.98 ± 1.91 to 26.60 ± 2.24 µM) compared to 5-fluorouracil, the reference drug, (IC~50~ = 41.26 ± 3.77 µM). In addition, compounds **5d**, **5i**, **5v**, and **5w** with IC~50~ = 31.97 ± 3.07, 32.80 ± 3.17, 30.34 ± 3.01 and 28.17 ± 2.24 µM, respectively, displayed good activity against MDA-MB-468. On the other hand, compounds **5b**, **5c**, **5g**, **5h**, and **5u** were moderately active against MDA-MB-468 with IC~50~ values ranging from 50.78 ± 5.11 to 74.25 ± 6.23 µM.

### 2.3.2. Structure Activity Relationship Study (SAR Study) of the Target Compounds {#sec2dot3dot2-ijms-17-01221}

Observing the results in [Table 4](#ijms-17-01221-t004){ref-type="table"}, valuable data could be extracted regarding the structure activity correlation of our compounds. Foremost, the effect of grafting diverse substituents on the terminal aryl moiety on the activities of the synthesized compounds **5a**--**t** was closely investigated. Compound **5a** bearing unsubstituted phenyl group showed good activity (IC~50~ = 22.31 ± 2.04 µM) in comparison to 5-fluorouracil (IC~50~ = 41.26 ± 3.77 µM), implying a doubling of the anti-proliferative activity.

Introduction of fluorine atom, a classical bioisostere of the hydrogen atom, at the 4-position as in compound **5f** resulted in comparable activity to the unsubstituted analogue **5a** (IC~50~ = 24.96 ± 2.55 and 22.31 ± 2.04 µM, respectively). Interestingly, transferring the fluorine atom from the 4-position to the 2-position, **5e**, resulted in an inactive derivative. Again, di-substitution with two fluorine atoms in the 2- and 4-positions, **5g**, was not favorable to the activity (IC~50~ = 50.78 ± 5.11 µM) compared to the mono 4-F substituted derivative **5f** (IC~50~ = 24.96 ± 2.55 µM). Incorporation of more bulky halogens as chlorine and bromine led to compounds **5d** and **5h**, respectively, with decreased activity (IC~50~ = 31.97 ± 3.07 and 53.83 ± 6.53 µM, respectively), suggesting that incorporation of a small halogen fluorine atom only in the 4-position is markedly advantageous to the activity. The order of activities of the halogenated derivatives **5d**--**h** decreased in the order of 4-F \> 4-Cl \> 2,4-di-F \> 4-Br \> 2-F. Also, grafting an electron-withdrawing nitro group as in compound **5i** resulted only in moderate improvement of the activity (IC~50~ = 32.80 ± 3.17 µM) compared to 5-FU (IC~50~ = 41.26 ± 3.77 µM), while introduction of methyl or amino groups, electron-donating groups, reduced the activity against MDA-MB-468, as shown in **5b** and **5c** analogs (IC~50~ = 74.25 ± 6.23 and 53.79 ± 5.02 µM, respectively). Contrariwise, substitution with electron-donating hydroxyl, methoxy, or ethoxy groups as in compounds **5j**--**t** maintained the activity in the good range of activity regardless of their positions or numbers (IC~50~ = (19.90 ± 1.37)--(26.60 ± 2.24) µM).

On the other hand, scrutinizing the anti-proliferative activity of compounds **5u**--**w** gave us insight about the effect of exchanging the phenyl group of **5a** for other aryl or heteroaryl moieties. Replacement of the phenyl ring of **5a** with a naphthalin-2-yl group in compound **5u** decreased the activity (IC~50~ = 66.45 ± 7.12 µM). Moreover, bioisosteric replacement of the phenyl moiety with 2-furyl or 2-thienyl groups (compounds **5v** and **5w**) moderately reduced the activity (IC~50~ = 30.34 ± 3.01 and 28.17 ± 2.24 µM, respectively). In conclusion, we can assume that incorporation of an unsubstituted phenyl group or its substitution with electron-donating hydroxyl, methoxy, or ethoxy groups is beneficial for activity against the MDA-MB-468 cell line, while introduction of heterocycles, such as 2-furyl or 2-thienyl, could not effectively replace the phenyl ring.

### 2.3.3. Cell-Cycle Analysis and Apoptotic Changes Investigation of Compound **5k** {#sec2dot3dot3-ijms-17-01221}

Cell reproduction necessitates DNA replication with a concomitant nuclear division followed by cytoplasmic partitioning to sporulate two daughter cells. Such a successive routine is known as the "cell cycle" and involves four distinguishable phases. The G1 phase is a gap integrated between the M phase (nuclear division) and the S phase (DNA synthesis); another gap called G2 phase also occurs between S and M. These gaps permit the repair of DNA damage and replication errors \[[@B38-ijms-17-01221]\].

To understand the mechanism behind the tumor suppression activity of the prepared compounds, the most active member in this study, **5k**, was selected to be further investigated regarding its effects on cell cycle progression and its potential apoptotic effects in the MDA-MB-468 cell line. The MDA-MB-468 cells were treated with IC~50~ concentration of compound **5k** for 24 h and its effect on the normal cell cycle was detected by fluorescence-activated cell sorting (FACS) analysis ([Figure 5](#ijms-17-01221-f005){ref-type="fig"}, [Figure S2](#app1-ijms-17-01221){ref-type="app"}). Interestingly, exposure of MDA-MB-468 cells to **5k** induced a remarkable augmentation in the proportion of cells at pre-G1 phase by 8.13-fold. The increase was accompanied by concomitant noteworthy mitigation in the percentage of cells at the G0/G1, S, and G2/M phases by 2.21-, 2.43-, and 11.83-fold in comparison to the control, respectively.

### 2.3.4. Evaluation of the Apoptotic Effect of Compound **5k** by Fluorescein Isothiocyanate (FITC)-Labeled Annexin V (Annexin V--FITC) Assay {#sec2dot3dot4-ijms-17-01221}

The apoptotic effect of **5k** was further evaluated by Annexin VFITC/PI (AV/PI) dual staining assay to examine the occurrence of phosphatidylserine externalization and also to understand whether it is due to physiological apoptosis or nonspecific necrosis.

In this study MDA-MB-468 cells were treated with compound **5k** for 48 h at 19.9 µM (IC~50~) to examine the apoptotic effect. It was observed that **5k** showed significant apoptosis against MDA-MB-468 cells, as shown in [Figure 6](#ijms-17-01221-f006){ref-type="fig"} and [Figure 7](#ijms-17-01221-f007){ref-type="fig"}. Results indicated that **5k** showed 75.78% of apoptosis at 19.9 µM whereas 27.06% of apoptosis was observed in the control (untreated cells), comprising a 2.8-fold improvement compared to the control. This experiment suggests that **5k** significantly induces apoptosis in MDA-MB-468 cells.

2.4. 2 Dimensional-Quantitative Structure Activity Relationship (2D-QSAR) Analysis for the Anti-Proliferative Activity of the Prepared Derivatives ***5a***--***w*** {#sec2dot4-ijms-17-01221}
--------------------------------------------------------------------------------------------------------------------------------------------------------------------

### 2.4.1. Elaboration of QSAR Model {#sec2dot4dot1-ijms-17-01221}

QSAR analysis of the anti-tumor activity of the prepared derivatives **5a**--**w** was performed to establish a correlation between the biochemical data and the compound structures; moreover, it aids us in identifying the positive and negative structural features within the three scaffolds. DS 2.5 software (Discovery Studio 2.5, Accelrys, Co., Ltd., Accelrys, San Diego, CA, USA) was used to run the analysis.

A set of 21 synthesized derivatives (**5a**--**d**, **5f**--**I**, and **5k**--**w**) was applied as a training set with their experimentally detected logIC~50~ against the MDA-MB-468 cancer cell line in the QSAR modeling. The two remaining synthesized members were used as an external test set to assess the predictive power and validate the established QSAR model. Various molecular descriptors for the training set molecules were calculated using the "Calculate Molecular Properties" module. 2D Descriptors entangled: topological descriptors, molecular properties, molecular property counts, AlogP, surface area, and volume. As for the 3D descriptors: dipole, principal moments of inertia, jurs descriptors, surface area, and volume, and shadow indices. To search for the best QSAR regression equation, genetic function approximation (GFA) was utilized, i.e., multiple linear regression modeling (MLR).

### 2.4.2. QSAR Study Results {#sec2dot4dot2-ijms-17-01221}

The best performing QSAR model is represented by Equation (1);

Potency (LogIC~50~) against MDA-MB-468 cell line

LogIC

50

= 4.1269 + 0.0599 Num_ExplicitAtoms − 0.0139 Molecular_SAVol + 3.0316 CHI_V\_3_C − 0.0920 Jurs_RPCS

Adopting Equation (1), QSAR model was graphically represented. This was accomplished by plotting the experimental values against the predicted bioactivity values logIC~50~ for the training set compounds, as shown in [Figure 8](#ijms-17-01221-f008){ref-type="fig"}. Also, the estimated and experimental activities data and the calculated descriptors of the training set compounds were summarized in [Table 5](#ijms-17-01221-t005){ref-type="table"}. The Least-Squares method was used to build the models, *r*^2^ = 0.842, *r*^2^ (adj) = 0.803, *r*^2^ (pred) = 0.795, Least-Squared error = 0.004 for model 1, where *r*^2^ (adj) is *r*^2^ adjusted for the number of terms in the model; *r*^2^ (pred) is the prediction *r*^2^, equivalent to *q*^2^ from a leave-one-out cross-validation.

### 2.4.3. QSAR Validation {#sec2dot4dot3-ijms-17-01221}

Two of the prepared compounds (**5e** and **5j**) were utilized to carry out the external validation of the determined QSAR equation. **5e** and **5j** were chosen as they exhibit mild and excellent activities. The observed activities versus those provided by QSAR study are presented in [Table 6](#ijms-17-01221-t006){ref-type="table"}.

2.5. Theoretical Kinetic ADME Study of the Target Derivatives **5a**--**w** {#sec2dot5-ijms-17-01221}
---------------------------------------------------------------------------

A theoretical kinetic study carried out by Discovery Studio 2.5 software (Accelrys) was adopted to predict the ADME of the prepared derivatives **5a**--**w**, [Table 7](#ijms-17-01221-t007){ref-type="table"}. The lipophilicity was evaluated by calculating AlogP98, whereas the PSA_2D descriptor was adopted to estimate the polar surface area. Moreover, solubility level was predicted where all members of this study seemed to possess low solubility. In accordance with this anticipation, absorption levels implicate that they are well absorbed. Also, they are predicted to be non-inhibitors of CYP2D not to mention compounds **5b**, **5q**, and **5s**, which are expected to inhibit CYP2D. LogP for compound **5k** was determined experimentally and found to equal 3.75. It is worth mentioning that all compounds passed Lipinski's rule of five.

3. Discussion {#sec3-ijms-17-01221}
=============

In summary, a novel series of 2-((benzimidazol-2-yl)thio)-1-arylethan-1-one derivatives **5a**--**w** has been synthesized**.** Their anti-proliferative activity against triple-negative breast cancer MDA-MB-468 cells was evaluated. Compound **5k** was found to be the most active compound in this study with IC~50~ value of 19.90 ± 1.37 µM as it was 2.1 times more potent and efficacious than 5-fluorouracil (IC~50~ = 41.26 ± 3.77 µM). Also, analogs **5a**, **5f**, and **5j**--**t** possessed excellent anti-proliferative activity with IC~50~ values ranging from 21.98 ± 1.91 to 26.60 ± 2.24 µM, which are better than the used reference drug. The preliminary SAR study showed that incorporation of unsubstituted phenyl group or its substitution with electron-donating hydroxyl, methoxy, or ethoxy groups are essential elements for the anti-tumor activity against MDA-MB-468, while introduction of heterocycles, such as 2-furyl or 2-thienyl, could not effectively replace the phenyl ring. In a cell-cycle analysis, compound **5k** increased the percentage of MDA-MB-468 cells at pre-G1 by 8.13-fold and G2/M phase by 11.83-fold. Furthermore, treatment of MDA-MB-468 cells with **5k** led to a marked increase in the percentage of annexin V--FITC-positive apoptotic cells (UR + LR) by 2.8-fold compared to the control. In addition, a QSAR model was established to investigate the structural requirements controlling activity against MDA-MB-468. Of note, the anticipated activities by the QSAR model were very near to the experimentally determined activities. Accordingly, this model could be conveniently applied for the prediction of more effective hits bearing the same structural framework. A theoretical kinetic study was constituted to anticipate the ADME of the prepared benzimidazoles. Moreover, single crystal X-ray diffraction has been included for compounds **4u** and **5v**.

Through this work we planned to add a scientific contribution for the treatment of the resistant type; TNBC by exploring different 2-benzimidazole derivatives. Our design was inspired by previously reported active scaffolds. Among the designed and synthetized molecules, many of them showed 2-fold increase in activity compared to 5-FU; this led us to develop a fruitful SAR analysis that will be a guideline for our future work.

4. Experimental {#sec4-ijms-17-01221}
===============

4.1. Chemistry {#sec4dot1-ijms-17-01221}
--------------

### 4.1.1. General {#sec4dot1dot1-ijms-17-01221}

Melting points were determined using a Gallenkamp melting point apparatus (WeissTechnik, Loughborough, UK) and are uncorrected. Infrared (IR) Spectra were recorded as KBr disks using the Perkin Elmer FT-IR Spectrum BX apparatus (PerkinElmer, Boston, MA, USA). Mass spectra were measured on an Agilent TripleQuadrupole 6410 QQQ LC/MS equipped with an ESI (electrospray ionization) source (Agilent Technologies, Santa Clara, CA, USA). NMR Spectra were recorded on a Bruker NMR spectrometer (Bruker, Karlsruhe, Germany). ^1^H spectrum was run at 500 MHz and ^13^C spectrum was run at 125 MHz in deuterated dimethyl sulfoxide (DMSO-*d*~6~). Chemical shifts are expressed in δ values (ppm) using the solvent peak as internal standard. All coupling constant (*J*) values are given in hertz. The abbreviations used are as follows: s, singlet; d, doublet; m, multiplet. Elemental analyses were carried out at the Regional Center for Mycology and Biotechnology, Al-Azhar University, Cairo, Egypt. Analytical thin layer chromatography (TLC) on silica gel plates containing UV indicator (Merck KGaA, Darmstadt, Germany) was employed routinely to follow the course of reactions and to check the purity of products. All reagents and solvents were purified and dried by standard techniques. Compounds **4** & **5a**, **b**, **f**, **h**, **4** & **5l**--**o**, **4** & **5q**, **r**, **t**, **v**, and **w**, are previously reported \[[@B28-ijms-17-01221]\].

### 4.1.2. Benzoimidazole-2-Thiol **2** {#sec4dot1dot2-ijms-17-01221}

Prepared according to the reported procedures \[[@B39-ijms-17-01221]\].

### 4.1.3. General Procedures for Synthesis of Sulfate Salts **4a**--**w** {#sec4dot1dot3-ijms-17-01221}

Prepared according to the reported procedures \[[@B28-ijms-17-01221]\].

2-((2-(4-Aminophenyl)-2-oxoethyl)thio)-1*H*-benzo\[d\]imidazol-3-ium sulfate (**4c**). White crystals, (yield 97%), m.p. 210--213 °C; IR (KBr, *ν* cm^−1^): 3450 (NH) and 1684 (C=O); ^1^H-NMR (DMSO-*d*~6~) δ ppm: 5.23 (s, 2H, CH~2~), 6.65 (d, 2H, H-3 and H-5 of 4-NH~2~C~6~H~4~, *J* = 8.5 Hz), 6.70 (s, 2H, NH~2~), 7.49--7.51 (m, 2H, H-5 and H-6 of 2-mercaptobenzimidazole), 7.71--7.73 (m, 2H, H-4 and H-7 of 2-mercaptobenzimidazole), 7.87 (d, 2H, H-2 and H-6 of 4-NH~2~C~6~H~4~, *J* = 8.5 Hz), 10.55 (s, 1H, NH), 12.64 (s, 1H, NH); ^13^C-NMR (DMSO-*d*~6~) δ ppm: 41.55 (CH~2~), 113.40, 113.59, 114.66, 125.76, 130.92, 131.62, 132.74, 151.68, 189.11, 195.74 (C=O); ESI MS *m*/*z*: 665 \[M + 1\]^+^; Anal. Calcd. for C~30~H~28~N~6~O~6~S~3~: C, 54.20; H, 4.25; N, 12.64; Found C, 54.28; H, 4.21; N, 12.75.

2-((2-(4-Chlorophenyl)-2-oxoethyl)thio)-1*H*-benzo\[d\]imidazol-3-ium sulfate (**4d**). White crystals, (yield 98%), m.p. 227--230 °C; IR (KBr, *ν* cm^−1^): 3400 (NH) and 1683 (C=O); ^1^H-NMR (DMSO-*d*~6~) δ ppm: 5.29 (s, 2H, CH~2~), 7.37--7.40 (m, 2H, H-5 and H-6 of 2-mercaptobenzimidazole), 7.62--7.65 (m, 2H, H-4 and H-7 of 2-mercaptobenzimidazole), 7.68 (d, 2H, H-3 and H-5 of 4-ClC~6~H~4~, *J* = 8.5 Hz), 8.08 (d, 2H, H-2 and H-6 of 4-ClC~6~H~4~, *J* = 8.5 Hz), 10.55 (s, 1H, NH), 12.61 (s, 1H, NH); ^13^C-NMR (DMSO-*d*~6~) δ ppm: 56.50 (CH~2~), 113.84, 120.85, 122.77, 124.68, 129.53, 130.89, 134.12, 134.86, 139.48, 150.64, 192.07 (C=O); ESI MS *m*/*z*: 703 \[M + 1\]^+^, 704 \[M + 2\]^+^; Anal. Calcd. for C~30~H~24~Cl~2~N~4~O~6~S~3~: C, 15.21; H, 3.44; N, 7.96; Found C, 15.30; H, 3.49; N, 8.02.

2-((2-(2-Fluorophenyl)-2-oxoethyl)thio)-1*H*-benzo\[d\]imidazol-3-ium sulfate (**4e**). White crystals, (yield 97%), m.p. 219--222 °C; IR (KBr, *ν* cm^−1^): 3435 (NH) and 1669 (C=O); ^1^H-NMR (DMSO-*d*~6~) δ ppm: 5.15 (s, 2H, CH~2~), 7.37--7.40 (m, 2H, H-5 and H-6 of 2-mercaptobenzimidazole), 7.41--7.48 (m, 2H, Ar--H), 7.60--7.62 (m, 2H, H-4 and H-7 of 2-mercaptobenzimidazole), 7.75--7.79 (m, 1H, Ar--H), 7.94 (t, 1H, H-6 of 2-FC~6~H~4~, *J* = 7.5 Hz), 10.64 (s, 1H, NH), 12.73 (s, 1H, NH). ESI MS *m*/*z*: 671 \[M + 1\]^+^; Anal. Calcd. for C~30~H~24~F~2~N~4~O~6~S~3~: C, 53.72; H, 3.61; N, 8.35; Found C, 53.67; H, 3.65; N, 8.38.

2-((2-(2,4-Difluorophenyl)-2-oxoethyl)thio)-1*H*-benzo\[d\]imidazol-3-ium sulfate (**4g**). White crystals, (yield 96%), m.p. 206--209 °C; IR (KBr, *ν* cm^−1^): 3468 (NH) and 1680 (C=O); ^1^H-NMR (DMSO-*d*~6~) δ ppm: 5.27 (s, 2H, CH~2~), 7.30 (t, 1H, Ar--H, *J* = 8.5 Hz), 7.43--7.46 (m, 2H, H-5 and H-6 of 2-mercaptobenzimidazole), 7.52 (t, 1H, Ar--H, *J* = 9.0 Hz), 7.65--7.69 (m, 2H, H-4 and H-7 of 2-mercaptobenzimidazole), 8.03 (t, 1H, Ar--H, *J* = 9.0 Hz),10.52 (s, 1H, NH), 12.67 (s, 1H, NH); ^13^C-NMR (DMSO-*d*~6~) δ ppm: 44.06 (CH~2~), 105.70, 105.91, 106.12, 113.09, 113.27, 113.76, 120.81, 125.25, 133.50, 133.85, 150.71, 189.03 (C=O). ESI MS *m*/*z*: 707 \[M + 1\]^+^; Anal. Calcd. for C~30~H~22~F~4~N~4~O~6~S~3~: C, 50.99; H, 3.14; N, 7.93; Found C, 50.91; H, 3.18; N, 8.01.

2-((2-(2-Hydroxyphenyl)-2-oxoethyl)thio)-1*H*-benzo\[d\]imidazol-3-ium sulfate (**4j**). White crystals, (yield 98%), m.p. 238--240 °C; IR (KBr, *ν* cm^−1^): 3466 (NH) and 1684 (C=O); ^1^H-NMR (DMSO-*d*~6~) δ ppm: 5.30 (s, 2H, CH~2~), 7.02--7.11 (m, 4H, Ar--H), 7.38--7.42 (m, 2H, H-5 and H-6 of 2-mercaptobenzimidazole), 7.67--7.70 (m, 2H, H-4 and H-7 of 2-mercaptobenzimidazole), 9.59 (s, 1H, OH), 10.60 (s, 1H, NH), 12.87 (s, 1H, NH). ESI MS *m*/*z*: 667 \[M + 1\]^+^, 668 \[M + 2\]^+^; Anal. Calcd. for C~30~H~26~N~4~O~8~S~3~: C, 54.04; H, 3.93; N, 8.40; Found C, 54.12; H, 3.91; N, 8.46.

2-((2-(3-Hydroxyphenyl)-2-oxoethyl)thio)-1*H*-benzo\[d\]imidazol-3-ium sulfate (**4k**). White crystals, (yield 97%), m.p. 228--230 °C; IR (KBr, *ν* cm^−1^): 3418 (NH) and 1670 (C=O); ^1^H-NMR (DMSO-*d*~6~) δ ppm: 5.34 (s, 2H, CH~2~), 7.11 (d, 1H, H-4 of 3-OHC~6~H~4~, *J* = 8.0 Hz), 7.40--7.44 (m, 2H, H-2 and H-3 of 3-OHC~6~H~4~), 7.47--7.49 (m, 2H, H-5 and H-6 of 2-mercaptobenzimidazole), 7.54 (d, 1H, H-6 of 3-OHC~6~H~4~, *J* = 8.0 Hz), 7.70--7.72 (m, 2H, H-4 and H-7 of 2-mercaptobenzimidazole), 9.73 (s, 1H, OH), 10.48 (s, 1H, NH), 12.61 (s, 1H, NH); ^13^C-NMR (DMSO-*d*~6~) δ ppm: 41.58 (CH~2~), 113.69, 115.09, 120.03, 121.82, 125.59, 130.55, 133.19, 136.46, 151.08, 158.23, 192.52 (C=O). ESI MS *m*/*z*: 667 \[M + 1\]^+^; Anal. Calcd. for C~30~H~26~N~4~O~8~S~3~: C, 54.04; H, 3.93; N, 8.40; Found C, 54.13; H, 4.03; N, 8.46.

2-((2-(2,4-Dimethoxyphenyl)-2-oxoethyl)thio)-1*H*-benzo\[d\]imidazol-3-ium sulfate (**4p**). White crystals, (yield 98%), m.p. 235--237 °C; IR (KBr, *ν* cm^−1^): 3377 (NH) and 1680 (C=O); ^1^H-NMR (DMSO-*d*~6~) δ ppm: 3.88 (s, 3H, OCH~3~), 4.00 (s, 3H, OCH~3~), 5.08 (s, 2H, CH~2~), 6.67 (d, 1H, H-5 of 2,4-(OCH~3~)~2~C~6~H~3~, *J* = 9.0 Hz), 6.74 (s, 1H, H-3 of 2,4-(OCH~3~)~2~C~6~H~3~), 7.43--7.44 (m, 2H, H-5 and H-6 of 2-mercaptobenzimidazole), 7.65--7.66 (m, 2H, H-4 and H-7 of 2-mercaptobenzimidazole), 7.79 (d, 1H, H-6 of 2,4-(OCH~3~)~2~C~6~H~3~, *J* = 9.0 Hz), 10.46 (s, 1H, NH), 12.37 (s, 1H, NH); ^13^C-NMR (DMSO-*d*~6~) δ ppm: 45.31 (CH~2~), 56.33 (OCH~3~), 56.73 (OCH~3~), 98.92, 107.24, 113.37, 117.65, 121.38, 125.12, 133.06, 151.57, 162.02, 165.95, 191.78 (C=O). ESI MS *m*/*z*: 755 \[M + 1\]^+^; Anal. Calcd. for C~34~H~34~N~4~O~10~S~3~: C, 54.10; H, 4.54; N, 7.42; Found C, 54.16; H, 4.59; N, 7.38.

2-((2-(3,4,5-Trimethoxyphenyl)-2-oxoethyl)thio)-1*H*-benzo\[d\]imidazol-3-ium sulfate (**4s**). White crystals, (yield 98%), m.p. 213--215 °C; IR (KBr, *ν* cm^−1^): 3427 (NH) and 1675 (C=O); ^1^H-NMR (DMSO-*d*~6~) δ ppm: 3.77 (s, 6H, 2OCH~3~), 3.89 (s, 12H, 4OCH~3~), 5.29 (s, 4H, 2CH~2~), 7.40--7.67 (m, 12H, Ar--H), 10.67 (s, 2H, 2NH), 12.49 (s, 2H, 2NH). ESI MS *m*/*z*: 815 \[M + 1\]^+^, 816 \[M + 2\]^+^; Anal. Calcd. for C~36~H~38~N~4~O~12~S~3~: C, 53.06; H, 4.70; N, 6.88; Found C, 52.96; H, 4.63; N, 6.80.

2-((2-(Naphthalen-2-yl)-2-oxoethyl)thio)-1*H*-benzo\[d\]imidazol-3-ium sulfate (**4u**). White crystals, (yield 96%), m.p. 246--250 °C; IR (KBr, *ν* cm^−1^): 3412 (NH) and 1670 (C=O); ^1^H-NMR (DMSO-*d*~6~) δ ppm: 5.38 (s, 2H, CH~2~), 7.31--7.33 (m, 2H, H-5 and H-6 of 2-mercaptobenzimidazole), 7.57--7.60 (m, 2H, H-4 and H-7 of 2-mercaptobenzimidazole), 7.66--7.74 (m, 2H, H-6 and H-7 of naphthalene), 8.04 (d, 2H, Ar--H, *J* = 8.5 Hz), 8.08 (d, 1H, Ar--H, *J* = 8.5 Hz), 8.17 (d, 1H, Ar--H, *J* = 8.0 Hz), 8.85 (s, 1H, H-1 of naphthalene), 10.54 (s, 1H, NH), 12.68 (s, 1H, NH); ^13^C-NMR (DMSO-*d*~6~) δ ppm: 56.49 (CH~2~), 113.96, 123.93, 124.13, 127.72, 128.26, 129.01, 130.14, 131.27, 132.56, 132.83, 135.79, 136.26, 150.58, 193.14 (C=O). ESI MS *m*/*z*: 735 \[M + 1\]^+^; Anal. Calcd. for C~38~H~30~N~4~O~6~S~3~: C, 62.11; H, 4.11; N, 7.62; Found C, 62.18; H, 4.13; N, 7.57.

### 4.1.4. General Procedure for Preparation of the Target Derivatives **5a**--**w** {#sec4dot1dot4-ijms-17-01221}

An aqueous solution (10 mL) of sodium bicarbonate was added to a stirred suspension of the adequate sulfate salts **4a**--**w** (4 mmol) in water (20 mL). The mixture was stirred for 2 h at room temperature. The obtained solid was collected by filtration, washed several times with water, then dried and recrystallized from ethanol to furnish compounds **5a**--**w**.

2-((1H-Benzo\[d\]imidazol-2-yl)thio)-1-(4-aminophenyl)ethan-1-one (**5c**). White crystals (yield 85%), m.p. 175--178 °C; IR (KBr, *ν* cm^−1^): 3412 (NH) and 1680 (C=O); ^1^H-NMR (DMSO-*d*~6~) δ ppm: 4.87 (s, 2H, CH~2~), 6.21 (s, 2H, NH~2~), 6.59 (d, 2H, H-3 and H-5 of 4-NH~2~C~6~H~4~, *J* = 9.0 Hz), 7.10--7.14 (m, 4H, H-4, H-5, H-6 and H-7 of 2-mercaptobenzimidazole), 7.76 (d, 2H, H-2 and H-6 of 4-NH~2~C~6~H~4~, *J* = 8.5 Hz), 12.53 (s, 1H, NH); ^13^C-NMR (DMSO-*d*~6~) δ ppm: 40.57 (CH~2~), 109.93, 113.03, 121.82, 122.78, 123.27, 131.42, 132.70, 150.41, 154.72, 190.66 (C=O); ESI MS *m*/*z*: 284 \[M + 1\]^+^; Anal. Calcd. for C~15~H~13~N~3~OS: C, 63.58; H, 4.62; N, 14.83; Found C, 63.81; H, 4.60; N, 14.89.

2-((1H-Benzo\[d\]imidazol-2-yl)thio)-1-(4-chlorophenyl)ethan-1-one (**5d**). White crystals (yield 90%), m.p. 179--181 °C (reported: 189--191 °C \[[@B40-ijms-17-01221]\]); IR (KBr, *ν* cm^−1^): 3410 (NH) and 1675 (C=O); ^1^H-NMR (DMSO-*d*~6~) δ ppm: 5.04 (s, 2H, CH~2~), 7.09--7.13 (m, 2H, H-5 and H-6 of 2-mercaptobenzimidazole), 7.40--7.42 (m, 2H, H-4 and H-7 of 2-mercaptobenzimidazole), 7.64 (d, 2H, H-3 and H-5 of 4-ClC~6~H~4~, *J* = 8.0 Hz), 8.08 (d, 2H, H-2 and H-6 of 4-ClC~6~H~4~, *J* = 8.5 Hz), 12.64 (s, 1H, NH); ^13^C-NMR (DMSO-*d*~6~) δ ppm: 40.49 (CH~2~), 112.45, 121.87, 129.41, 130.82, 134.67, 139.06, 149.82, 193.09 (C=O); ESI MS *m*/*z*: 302.9 \[M\]^+^, 304.9 \[M + 2\]^+^.

2-((1H-Benzo\[d\]imidazol-2-yl)thio)-1-(2-fluorophenyl)ethan-1-one (**5e**). White crystals (yield 89%), m.p. 145--148 °C; IR (KBr, *ν* cm^−1^): 3420 (NH) and 1654 (C=O); ^1^H-NMR (DMSO-*d*~6~) δ ppm: 4.93 (s, 2H, CH~2~), 7.09--7.12 (m, 2H, H-5 and H-6 of 2-mercaptobenzimidazole), 7.37--7.49 (m, 4H, Ar--H), 7.70--7.74 (m, 1H, Ar--H), 8.08 (t, 1H, Ar--H, *J* = 7.5 Hz), 12.66 (s, 1H, NH); ^13^C-NMR (DMSO-*d*~6~) δ ppm: 43.11 (CH~2~), 109.23, 117.29, 118.50, 121.69, 122.18, 124.61, 125.38, 131.09, 136.01, 149.80, 157.31, 160.50, 162.52, 191.90 (C=O); ESI MS *m*/*z*: 287 \[M + 1\]^+^, 288 \[M + 2\]^+^; Anal. Calcd. for C~15~H~11~FN~2~OS: C, 62.92; H, 3.87; N, 9.78; Found C, 63.09; H, 3.90; N, 9.84.

2-((1H-Benzo\[d\]imidazol-2-yl)thio)-1-(2,4-difluorophenyl)ethan-1-one (**5g**). White crystals (yield 94%), m.p. 116--120 °C; IR (KBr, *ν* cm^−1^): 3420 (NH) and 1675 (C=O); ^1^H-NMR (DMSO-*d*~6~) δ ppm: 4.91 (s, 2H, CH~2~), 7.08--7.12 (m, 2H, H-5 and H-6 of 2-mercaptobenzimidazole), 7.26 (t, 1H, Ar--H, *J* = 8.5 Hz), 7.39--7.41 (m, 2H, H-4 and H-7 of 2-mercaptobenzimidazole), 7.47 (t, 1H, Ar--H, *J* = 9 Hz), 8.00 (q, 1H, Ar--H, *J* = 8.5 Hz), 12.61 (s, 1H, NH); ^13^C-NMR (DMSO-*d*~6~) δ ppm: 42.95 (CH~2~), 105.54, 105.75, 105.96, 112.89, 113.04, 121.88, 133.35, 149.73, 190.71 (C=O); ESI MS *m*/*z*: 304 \[M\]^+^, 305 \[M + 1\]^+^; Anal. Calcd. for C~15~H~10~F~2~N~2~OS: C, 59.20; H, 3.31; N, 9.21; Found C, 59.46; H, 3.29; N, 9.32.

2-((1H-Benzo\[d\]imidazol-2-yl)thio)-1-(2-hydroxyphenyl)ethan-1-one (**5j**). White crystals (yield 85%), m.p. 205--208 °C (reported: 201 °C \[[@B41-ijms-17-01221]\]); IR (KBr, *ν* cm^−1^): 3408 (NH) and 1670 (C=O); ^1^H-NMR (DMSO-*d*~6~) δ ppm: 4.91 (s, 2H, CH~2~), 6.99--7.15 (m, 4H, Ar--H), 7.38--7.41 (m, 2H, H-4 and H-7 of 2-mercaptobenzimidazole), 7.83--7.95 (m, 2H, Ar--H), 9.37 (s, 1H, OH), 12.53 (s, 1H, NH); ESI MS *m*/*z*: 285 \[M + 1\]^+^.

2-((1H-Benzo\[d\]imidazol-2-yl)thio)-1-(3-hydroxyphenyl)ethan-1-one (**5k**). White crystals (yield 87%), m.p. 228--230 °C (reported: 224--227 °C \[[@B42-ijms-17-01221]\]); IR (KBr, *ν* cm^−1^): 3336 (NH) and 1660 (C=O); ^1^H-NMR (DMSO-*d*~6~) δ ppm: 5.01 (s, 2H, CH~2~), 7.08--7.10 (m, 3H, H-5, H-6 of 2-mercaptobenzimidazole and H-4 of 3-OHC~6~H~4~), 7.37--7.45 (m, 4H, H-4, H-7 of 2-mercaptobenzimidazole and H-5, H-6 of 3-OHC~6~H~4~), 7.54 (s, 1H, H-2 of 3-OHC~6~H~4~), 9.89 (s, 1H, OH), 12.61 (s, 1H, NH); ^13^C-NMR (DMSO-*d*~6~) δ ppm: 40.47 (CH~2~), 114.96, 119.86, 121.28, 121.61, 130.43, 137.23, 150.01, 158.14, 193.72 (C=O); ESI MS *m*/*z*: 285.

2-((1H-Benzo\[d\]imidazol-2-yl)thio)-1-(2,4-dimethoxyphenyl)ethan-1-one (**5p**). White crystals (yield 92%), m.p. 208--211 °C; IR (KBr, *ν* cm^−1^): 3413 (NH) and 1655 (C=O); ^1^H-NMR (DMSO-*d*~6~) δ ppm: 3.92 (s, 3H, OCH~3~), 3.96 (s, 3H, OCH~3~), 4.80 (s, 2H, CH~2~), 6.65 (d, 1H, H-5 of 2,4-(OCH~3~)~2~C~6~H~3~, *J* = 9.0 Hz), 6.71 (s, 1H, H-3 of 2,4-(OCH~3~)~2~C~6~H~3~), 7.06--7.09 (m, 2H, H-5 and H-6 of 2-mercaptobenzimidazole), 7.40--7.41 (m, 2H, H-4 and H-7 of 2-mercaptobenzimidazole), 7.73 (d, 1H, H-6 of 2,4-(OCH~3~)~2~C~6~H~3~, *J* = 8.5 Hz), 12.60 (s, 1H, NH); ^13^C-NMR (DMSO-*d*~6~) δ ppm: 43.97 (CH~2~), 56.20 (OCH~3~), 56.60 (OCH~3~), 98.88, 104.25, 106.96, 110.65, 114.19, 118.27, 121.63, 132.88, 150.15, 161.52, 165.36, 193.07 (C=O); ESI MS *m*/*z*: 329 \[M + 1\]^+^; Anal. Calcd. for C~17~H~16~N~2~O~3~S: C, 62.18; H, 4.91; N, 8.53; Found C, 62.40; H, 4.94; N, 8.45.

2-((1H-Benzo\[d\]imidazol-2-yl)thio)-1-(3,4,5-trimethoxyphenyl)ethan-1-one (**5s**). White crystals (yield 88%), m.p. 233--235 °C; IR (KBr, *ν* cm^−1^): 3405 (NH) and 1670 (C=O); ^1^H-NMR (DMSO-*d*~6~) δ ppm: 3.77 (s, 3H, OCH~3~), 3.86 (s, 6H, OCH~3~), 5.04 (s, 2H, CH~2~), 7.12--7.43 (m, 6H, Ar--H), 12.68 (s, 1H, NH); ^13^C-NMR (DMSO-*d*~6~) δ ppm: 39.37 (CH~2~), 56.60 (OCH~3~), 60.67 (OCH~3~), 106.58, 121.92, 131.12, 142.73, 149.87, 153.29, 192.94 (C=O); Anal. Calcd. for C~18~H~18~N~2~O~4~S: C, 60.32; H, 5.06; N, 7.82; Found C, 60.41; H, 5.03; N, 7.75.

2-((1H-Benzo\[d\]imidazol-2-yl)thio)-1-(naphthalen-2-yl)ethan-1-one (**5u**). White crystals (yield 92%), m.p. 160--162 °C; IR (KBr, *ν* cm^−1^): 3415 (NH) and 1673 (C=O); ^1^H-NMR (DMSO-*d*~6~) δ ppm: 5.20 (s, 2H, C[H~2~]{.ul}), 7.10--7.13 (m, 2H, H-5 and H-6 of 2-mercaptobenzimidazole), 7.41--7.43 (m, 2H, H-4 and H-7 of 2-mercaptobenzimidazole), 7.64--7.72 (m, 2H, Ar--H), 8.02--8.07 (m, 3H, Ar--H), 8.15 (d, 1H, Ar--H, *J* = 8.0 Hz), 8.85 (s, 1H, H-1 of naphthalene), 12.80 (s, 1H, NH); ^13^C-NMR (DMSO-*d*~6~) δ ppm: 40.42 (CH~2~), 121.92, 124.19, 127.59, 128.20, 128.91, 129.42, 130.12, 131.11, 132.59, 133.19, 135.69, 149.99, 193.90 (C=O); ESI MS *m*/*z*: 319 \[M + 1\]^+^; Anal. Calcd. for C~19~H~14~N~2~OS: C, 71.68; H, 4.43; N, 8.80; Found C, 71.81; H, 4.40; N, 8.73.

4.2. Biological Evaluation {#sec4dot2-ijms-17-01221}
--------------------------

### 4.2.1. In Vitro Evaluation of the Anti-Proliferative Activity {#sec4dot2dot1-ijms-17-01221}

The synthesized derivatives **5a**--**w** was evaluated for their anti-proliferative activity via the Stem Cell Therapy and Tissue Reengineering Program in the King Faisal Specialized Hospital and Research Center, Riyadh, Saudi Arabia. In vitro anti-proliferative activity was measured by the cell growth inhibition assay. This assay was conducted using a WST-1 reagent (Sigma-Aldrich Chemie Gmbh, Munich, Germany) for determination of the IC~50~ for each compound and the results are given in [Table 4](#ijms-17-01221-t004){ref-type="table"}. MDA-MB-468 breast cancer cell line was purchased from the American Type Culture Collection (Manassas, Virginia, USA). Cells were maintained in Dulbecco's modified Eagle's medium (DMEM) (Sigma-Aldrich Chemie Gmbh), supplemented with 10% FBS (Lonza, Visp, Switzerland), 100 IU/mL penicillin, 100 mg/mL streptomycin, and 2 mmol/L [l]{.smallcaps}-glutamine (Sigma). Cells were seeded into 96-well plates at 0.4 × 10^4^/well and incubated overnight. The medium was replaced with a fresh one containing the desired concentrations of the test compounds. After 48 h, 10 µL of the WST-1 reagent were added to each well and the plates were re-incubated for 4 h at 37 °C. The amount of formazan was quantified using an ELISA reader (Thermo Fisher Scientific, Waltham, MA, USA) at 450 nm. The IC~50~ values were calculated according to the equation for Boltzmann sigmoidal concentration response curve using the nonlinear regression models (GraphPad, Prism Version 5, San Diego, CA, USA). The results reported are means of at least three separate experiments. Significant differences were analyzed by one-way analysis of variance (ANOVA) wherein the differences were considered to be significant at *p* \< 0.05.

### 4.2.2. Cell Cycle Analysis {#sec4dot2dot2-ijms-17-01221}

The MDA-MB-468 cells were subjected to treatment with 19.90 µM of compound **5k** for 24 h. Consequently, the cells were washed twice with ice-cold phosphate buffered saline (PBS). The treated cells were collected by centrifugation, fixed in ice-cold 70% (*v*/*v*) ethanol, washed with PBS, re-suspended with 0.1 mg/mL RNase, stained with 40 mg/mL PI, and analyzed by flow cytometry using FACScalibur (Becton Dickinson, BD, San Jose, CA, USA). The cell cycle distributions were calculated using CellQuest software (Becton Dickinson).

### 4.2.3. Annexin V--FITC Apoptosis Assay {#sec4dot2dot3-ijms-17-01221}

The MDA-MB-468 cells were seeded as described above and then incubated with 19.90 µM of compound **5k** for 24 h. Cells were harvested, washed twice with PBS, and centrifuged. In brief, 10^5^ of cells were treated with annexin V--FITC and propidium iodide (PI) using the apoptosis detection kit (BD Biosciences, San Jose, CA, USA) according to the manufacturer's protocol. Annexin V--FITC and PI binding were analyzed by flow cytometry on FACScalibur (BD Biosciences) without gating restrictions using 10,000 cells. Data were collected using logarithmic amplification of both the FL1 (FITC) and the FL2 (PI) channels. Quadrant analysis of co-ordinate dot plots was performed with CellQuest software. Unstained cells were used to adjust the photomultiplier voltage and for compensation setting adjustment to eliminate spectral overlap between the FL1 and the FL2 signal.
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![Structures of some reported benzimidazoles **I**--**VIII**, by other research groups, with anti-proliferative activity against triple-negative breast cancer MDA-MB-468 cells \[[@B22-ijms-17-01221],[@B23-ijms-17-01221],[@B24-ijms-17-01221],[@B25-ijms-17-01221],[@B26-ijms-17-01221],[@B27-ijms-17-01221]\].](ijms-17-01221-g001){#ijms-17-01221-f001}

![Structure-based design of target benzimidazoles **5a**--**w** as anti-triple-negative breast cancer (TNBC) agents.](ijms-17-01221-g002){#ijms-17-01221-f002}

![Synthesis of the target 2-((benzimidazol-2-yl)thio)-1-arylethan-1-ones **5a**--**w** and their corresponding sulfate salts **4a**--**w**. Reagents and conditions: (**i**) CS~2~/KOH/ethanol/reflux 2 h; (**ii**) Glacial acetic acid/reflux 0.5 h; (**iii**) Aqueous Na~2~CO~3~/r.t. (room temperature) 2 h.](ijms-17-01221-sch001){#ijms-17-01221-sch001}

![An ORTEP diagram of the final X-ray structure of compound **4u**.](ijms-17-01221-g003){#ijms-17-01221-f003}

![An ORTEP diagram of the final X-ray structure of compound **5v**.](ijms-17-01221-g004){#ijms-17-01221-f004}

![Bar chart shows percentage of MDA-MB-468 cells at each phase of cell cycle in control cells and cells treated with compound **5k**.](ijms-17-01221-g005){#ijms-17-01221-f005}

![Fluorescein isothiocyanate (FITC)-labeled annexin V (Annexin V--FITC) staining. The cells were treated with dimethylsulfoxide (DMSO) as a control or with compound **5k** at IC~50~ concentration for 24 h. The experiment was done in triplicate.](ijms-17-01221-g006){#ijms-17-01221-f006}

![Effect of compound **5k** on the percentage of annexin V--FITC-positive staining in MDA-MB-468 cells. Data are presented as means ± S.D. ^a^ Indicates statistical difference from control at *p* \< 0.0001.](ijms-17-01221-g007){#ijms-17-01221-f007}

![Predicted versus experimental logIC~50~ of the tested compounds against MDA-MB-468 cell line according to Equation (1) (*r*^2^ = 0.842).](ijms-17-01221-g008){#ijms-17-01221-f008}
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###### 

Crystallographic data and refinements for compounds **4u** and **5v**.

  Compound                                                                  4u                                                       5v
  ------------------------------------------------------------------------- -------------------------------------------------------- --------------------------------------------------------
  Crystal data                                                                                                                       
  Chemical formula                                                          2(C~19~H~15~N~2~OS) C~2~H~6~O·SO~4~                      C~13~H~10~N~2~O~2~S
  *M*r                                                                      780.94                                                   258.29
  Crystal system, space group                                               Orthorhombic, *P*2~1~2~1~2~1~                            Monoclinic, *P*2~1~/*c*
  Temperature (*K*)                                                         100                                                      100
  *a*, *b*, *c* (Å)                                                         14.2409 (8), 15.8339 (9), 16.2043 (8)                    11.4097 (7), 10.8336 (7), 10.1256 (7)
  β (°)                                                                     90.00                                                    114.165 (2)
  *V* (Å^3^)                                                                3653.9 (3)                                               1141.93 (13)
  *Z*                                                                       4                                                        4
  Radiation type                                                            Mo *Kα*                                                  Mo *Kα*
  µ (mm^−1^)                                                                0.26                                                     0.28
  Crystal size (mm)                                                         0.44 × 0.26 × 0.16                                       0.47 × 0.36 × 0.11
  Data collection                                                                                                                    
  Diffractometer                                                            CCD area detector diffractometer                         Bruker APEX-II D8 venture diffractometer
  Absorption correction                                                     multi-scan, SADABS                                       multi-scan, SADABS
  *T*~min~, *T*~max~                                                        0.90, 0.92                                               0.89, 0.93
  Number of measured, independent and observed \[I \> 2σ(I)\] reflections   11,220, 11,220, 8647                                     9364, 1999, 1689
  *R* ~int~                                                                                                                          0.090
  Refinement                                                                                                                         
  R\[*F*^2^ \> 2ó(*F*^2^)\], wR(*F*^2^), S                                  0.050, 0.121, 1.05                                       0.086, 0.250, 1.10
  Number of reflections                                                     11,220                                                   1999
  Number of parameters                                                      494                                                      163
  Number of restraints                                                      0                                                        0
  H-atom treatment                                                          by a mixture of independent and constrained refinement   by a mixture of independent and constrained refinement
  Δρ~max~, Δρ~min~ (e·Å^−3^)                                                0.76, −0.37                                              1.12, −0.87
  CCDC number                                                               1,058,838                                                1,455,648
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###### 

Selected geometric parameters (Å, °) for compound **4u**.

  -------------------- ------------- ---------------- -----------
  **Bond Distances**                                  
  S1A--C7A             1.722 (3)     O6--C21          1.437 (6)
  S1A--C8A             1.811 (3)     N1A--C7A         1.333 (4)
  S1B--C7B             1.724 (3)     N1A--C1A         1.406 (4)
  S1B--C8B             1.804 (3)     N2A--C6A         1.387 (4)
  S2--O3               1.476 (3)     N2A--C7A         1.338 (4)
  S2--O5               1.479 (3)     N1B--C7B         1.342 (4)
  S2--O2               1.478 (3)     N1B--C1B         1.398 (4)
  S2--O4               1.467 (2)     N2B--C7B         1.339 (4)
  O1A--C9A             1.203 (6)     N2B--C6B         1.381 (4)
  **Bond Angles**                                     
  C7A--S1A--C8A        102.76 (15)   N1A--C7A--N2A    109.8 (3)
  C7B--S1B--C8B        99.02 (15)    S1A--C7A--N1A    130.1 (2)
  O3--S2--O5           108.55 (14)   S1A--C8A--C9A    105.5 (2)
  O4--S2--O5           111.31 (14)   O1A--C9A--C10A   121.0 (4)
  O3--S2--O4           110.49 (14)   O1A--C9A--C8A    120.6 (3)
  O2--S2--O3           108.54 (16)   N1B--C1B--C2B    131.1 (3)
  O2--S2--O4           109.46 (15)   N1B--C1B--C6B    106.5 (3)
  O2--S2--O5           108.43 (14)   N2B--C6B--C5B    131.8 (3)
  C1A--N1A--C7A        108.2 (3)     N2B--C6B--C1B    107.0 (3)
  C6A--N2A--C7A        108.7 (3)     S1B--C7B--N1B    128.7 (3)
  C1B--N1B--C7B        108.0 (3)     S1B--C7B--N2B    121.3 (2)
  C6B--N2B--C7B        108.7 (3)     N1B--C7B--N2B    109.9 (3)
  N1A--C1A--C2A        130.9 (3)     S1B--C8B--C9B    107.8 (2)
  N1A--C1A--C6A        106.5 (3)     O1B--C9B--C10B   122.0 (3)
  N2A--C6A--C1A        106.9 (3)     O1B--C9B--C8B    120.4 (3)
  N2A--C6A--C5A        131.1 (3)     O6--C21--C20     111.9 (4)
  -------------------- ------------- ---------------- -----------
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###### 

Selected geometric parameters (Å, °) for compound **5v**.

  -------------------- ------------- -------------- -------------
  **Bond Distances**                                
  Cl1--C13             1.7361 (12)   N1--C1         1.3831 (13)
  S1--C7               1.7521 (10)   N1--C7         1.3686 (12)
  S1--C8               1.7949 (10)   N2--C6         1.3947 (13)
  S1--C8               1.7949 (10)   N2--C6         1.3947 (13)
  O1--C9               1.2146 (12)   N2--C7         1.3157 (12)
  **Bond Angles**                                   
  C6--S1--C7           102.2 (2)     S1--C6--C5     113.5 (4)
  C3--O1--C4           106.5 (4)     S1--C7--N2     117.3 (3)
  C7--N1--C8           103.8 (4)     N1--C7--N2     114.4 (5)
  C7--N2--C13          106.7 (4)     S1--C7--N1     128.4 (4)
  O1--C3--C2           111.2 (5)     N1--C8--C9     130.2 (4)
  O1--C4--C5           116.2 (4)     N1--C8--C13    109.6 (4)
  O1--C4--C1           109.8 (4)     N2--C13--C8    105.5 (5)
  O2--C5--C6           123.4 (5)     N2--C13--C12   132.2 (5)
  -------------------- ------------- -------------- -------------
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###### 

In vitro anti-proliferative activity of compounds **5a**--**w** against breast MDA-MB-468 cancer cell line.

  Compound             Aryl                          IC~50~ (µM) ^a^
  -------------------- ----------------------------- -----------------
  **5a**               C~6~H~5~                      22.31 ± 2.04
  **5b**               4-Me--C~6~H~4~                74.25 ± 6.23
  **5c**               4-NH~2~--C~6~H~4~             53.79 ± 5.02
  **5d**               4-Cl--C~6~H~4~                31.97 ± 3.07
  **5e**               2-F--C~6~H~4~                 NA ^b^
  **5f**               4-F--C~6~H~4~                 24.96 ± 2.55
  **5g**               2,4-di-F--C~6~H~3~            50.78 ± 5.11
  **5h**               4-Br--C~6~H~4~                53.83 ± 6.53
  **5i**               4-NO~2~--C~6~H~4~             32.80 ± 3.17
  **5j**               2-OH--C~6~H~4~                22.41 ± 2.13
  **5k**               3-OH--C~6~H~4~                19.90 ± 1.37
  **5l**               4-OH--C~6~H~4~                21.98 ± 1.91
  **5m**               2-OCH~3~--C~6~H~4~            22.32 ± 2.06
  **5n**               4-OCH~3~--C~6~H~4~            25.35 ± 2.15
  **5o**               3-OH-4-OCH~3~--C~6~H~3~       22.06 ± 1.93
  **5p**               2,4-(OCH~3~)~2~--C~6~H~3~     26.60 ± 2.24
  **5q**               3,4-(OCH~3~)~2~--C~6~H~3~     24.30 ± 2.13
  **5r**               3,4-O-CH~2~--*O*--C~6~H~3~    22.79 ± 1.87
  **5s**               3,4,5-(OCH~3~)~3~--C~6~H~2~   22.72 ± 2.03
  **5t**               4-OC~2~H~5~--C~6~H~4~         23.91 ± 2.19
  **5u**               naphthalin-2-yl               66.45 ± 7.12
  **5v**               furan-2-yl                    30.34 ± 3.01
  **5w**               thiophen-2-yl                 28.17 ± 2.24
  **5-Fluorouracil**                                 41.26 ± 3.77

^a^ IC~50~ values are the mean ± S.D. of three separate experiments; ^b^ NA: Compounds having IC~50~ value \> 100 µM.
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###### 

Estimated IC~50~ data of the training set against MDA-MB-468 cell line and calculated descriptors governing IC~50~ according to Equation (1).

  Compound   Experimental Activity (LogIC~50~)   Predicted Activity (LogIC~50~)   Residual   Num_ExplicitAtoms   Molecular_SAVol   CHI_V\_3_C   Jurs_RPCS
  ---------- ----------------------------------- -------------------------------- ---------- ------------------- ----------------- ------------ -----------
  **5a**     1.3485                              1.4134                           −0.0649    31                  414.53            0.429        0.817
  **5b**     1.8707                              1.8742                           −0.0035    34                  430.44            0.596        0.834
  **5c**     1.7307                              1.6624                           0.0683     33                  426.68            0.525        0.736
  **5d**     1.5047                              1.5789                           −0.0742    31                  443.37            0.618        0.860
  **5f**     1.3972                              1.4763                           −0.0791    31                  423.74            0.492        0.807
  **5g**     1.7057                              1.4841                           0.2216     31                  432.96            0.536        0.752
  **5h**     1.7310                              1.7260                           0.0050     31                  462.96            0.756        0.844
  **5i**     1.5159                              1.4788                           0.0371     33                  441.92            0.541        0.928
  **5k**     1.2989                              1.3084                           −0.0095    32                  423.66            0.504        3.675
  **5l**     1.3420                              1.3186                           0.0234     32                  423.66            0.504        3.563
  **5m**     1.3487                              1.3758                           −0.0271    35                  445.34            0.477        0.720
  **5n**     1.4040                              1.4366                           −0.0326    35                  445.34            0.497        0.727
  **5o**     1.3436                              1.3587                           −0.0151    36                  454.48            0.553        2.662
  **5p**     1.4249                              1.3990                           0.0259     39                  476.16            0.545        0.630
  **5q**     1.3856                              1.4065                           −0.0209    39                  476.16            0.547        0.616
  **5r**     1.3577                              1.4848                           −0.1271    34                  444.90            0.528        0.633
  **5s**     1.3564                              1.3416                           0.0148     43                  506.98            0.579        0.296
  **5t**     1.3786                              1.3311                           0.0475     38                  465.86            0.497        0.710
  **5u**     1.8225                              1.8264                           −0.0039    38                  452.50            0.628        1.671
  **5v**     1.4820                              1.4312                           0.0508     28                  396.29            0.405        0.637
  **5w**     1.4498                              1.4865                           −0.0367    28                  417.77            0.523        0.655
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###### 

External validation of the established QSAR model.

  Compound   Experimental Activity (LogIC~50~)   Predicted Activity (LogIC~50~)   Residual   Num_ExplicitAtoms   Molecular_SAVol   CHI_V\_3_C   Jurs_RPCS
  ---------- ----------------------------------- -------------------------------- ---------- ------------------- ----------------- ------------ -----------
  **5e**     2.1497                              2.1497                           0.00       31                  423.74            0.473        0.795
  **5j**     1.3504                              1.3504                           0.00       32                  423.66            0.482        3.313
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###### 

Computer-aided ADME study of the prepared derivatives.

  Compound   Alog*P*98 ^a^   PSA_2D ^b^   Solubility ^c^   Solubility Level ^d^   Absorption Level ^e^   CYP2D6 ^f^   CYP2D6 Probability ^g^
  ---------- --------------- ------------ ---------------- ---------------------- ---------------------- ------------ ------------------------
  **5a**     3.684           43.616       −4.830           2                      0                      0            0.316
  **5b**     4.171           43.616       −5.324           2                      0                      1            0.554
  **5c**     2.938           70.156       −4.307           2                      0                      0            0.376
  **5d**     4.349           43.616       −5.560           2                      0                      0            0.376
  **5e**     3.890           43.616       −5.158           2                      0                      0            0.336
  **5f**     3.890           43.616       −5.152           2                      0                      0            0.376
  **5g**     4.095           43.616       −5.478           2                      0                      0            0.326
  **5h**     4.433           43.616       −5.636           2                      0                      0            0.287
  **5i**     3.579           86.440       −5.034           2                      0                      0            0.257
  **5j**     3.442           64.432       −4.355           2                      0                      0            0.326
  **5k**     3.442           64.432       −4.363           2                      0                      0            0.336
  **5l**     3.442           64.432       −4.366           2                      0                      0            0.386
  **5m**     3.668           52.547       −4.911           2                      0                      0            0.376
  **5n**     3.668           52.547       −4.887           2                      0                      0            0.396
  **5o**     3.426           73.362       −4.486           2                      0                      0            0.425
  **5p**     3.652           61.477       −4.959           2                      0                      0            0.306
  **5q**     3.652           61.477       −4.949           2                      0                      1            0.524
  **5r**     3.453           61.477       −5.112           2                      0                      0            0.346
  **5s**     3.635           70.407       −5.013           2                      0                      1            0.554
  **5t**     4.017           52.547       −5.102           2                      0                      0            0.366
  **5u**     3.287           28.624       −4.870           2                      0                      0            0.306
  **5v**     3.080           56.171       −4.348           2                      0                      0            0.099
  **5w**     3.410           43.616       −4.643           2                      0                      0            0.425

^a^ Lipophilicity descriptor; ^b^ Polar surface area; ^c^ Solubility parameter. (0--−2 = optimal, −2--−4 = good, −4--−6 = low, −6--−8 = very low); ^d^ Solubility level. (0 = extremely low, 1 = very low but possible, 2 = low, 3 = good, 4 = optimal); ^e^ Absorption level. (0 = good, 1 = moderate, 2 = low, 3 = very low); ^f^ CYP2D inhibition. (0 = non inhibitor, 1 = inhibitor); ^g^ CYP2D6 Probability: 0--0.5 = non inhibitor; 0.5--1 = inhibitor.
